ArticleOpen access journal of contraception2026
Comparison of Dermatologic and Neuropsychological Side Effects of Oral Contraceptives, 2016-2020.
Article in Open access journal of contraception, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Many patients seek a contraceptive medication that lessens symptom burden of comorbid conditions. To date, there have been limited studies investigating how oral contraceptives compare in rates of skin and mood-related side effects. The goal of this study was to compare rates of dermatological and neuropsychological side effects with various oral contraceptive formulations. Patients and Methods: We utilized FDA Adverse Event Reporting System (FAERS) and Medical Expenditure Panel Survey (MEPS) data to compare rates of reported subjective side effects for oral contraception pills from 2016 to 2020, including acne, migraine, anxiety, and depression. Ethinyl estradiol/Norethindrone was used as the reference pill, as it is the oldest and the most prescribed combination oral contraceptive. Results: Pills with drospirenone had higher rates of acne, migraine, depression, and anxiety. Acne was also greater with levonorgestrel and norgestimate pills, and anxiety was greater with levonorgestrel combination pills and norethindrone alone. Conclusion: Oral contraceptive formulation may affect dermatologic and neuropsychological symptoms. Multiple progestins may impact rates of acne and anxiety, with fewer effects on depression and migraine headaches. This knowledge may allow for the personalization of medication selection based on the patients' other co-morbid conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.